Larson Financial Group LLC Purchases 119 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Larson Financial Group LLC lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 11.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,143 shares of the medical research company’s stock after purchasing an additional 119 shares during the quarter. Larson Financial Group LLC’s holdings in Bio-Rad Laboratories were worth $375,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC raised its stake in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 87 shares in the last quarter. Gladius Capital Management LP acquired a new position in Bio-Rad Laboratories in the 3rd quarter valued at $32,000. Asset Planning Inc bought a new position in Bio-Rad Laboratories in the 4th quarter worth $33,000. UMB Bank n.a. lifted its position in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after acquiring an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new stake in Bio-Rad Laboratories during the fourth quarter valued at about $38,000. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 4.5 %

Bio-Rad Laboratories stock opened at $249.43 on Tuesday. The business has a 50 day moving average price of $318.18 and a two-hundred day moving average price of $329.93. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12 month low of $244.19 and a 12 month high of $387.99. The stock has a market cap of $6.99 billion, a price-to-earnings ratio of -3.84 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BIO. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company cut their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Bio-Rad Laboratories has an average rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.